[1] 农晓黎,陈菲,詹浩洪,等. 体检人群非酒精性脂肪性肝病发病率及其相关危险因素分析. 实用肝脏病杂志,2024,27(3):353-356. [2] Godoy-Matos A F, Silva Júnior W S, Valerio C M. NAFLD as a continuum: from obesity to metabolic syndrome and diabetes. Diabetol Metab Syndr, 2020, 12(1): 1-20. [3] Frey S, Patouraux S, Debs T, et al. Prevalence of NASH/NAFLD in people with obesity who are currently classified as metabolically healthy. Surg Obes Relat Dis, 2020, 16(12): 2050-2057. [4] Lonardo A, Mantovani A, Lugari S, et al. Epidemiology and pathophysiology of the association between NAFLD and metabolically healthy or metabolically unhealthy obesity. Ann hepatol, 2020, 19(4): 359-366. [5] 阳韬,王潇,蒋龙凤,等. 巨噬细胞的异质性在非酒精性脂肪性肝病和非酒精性脂肪性肝炎疾病进展中的作用. 中华肝脏病杂志,2023,31(7):770-775. [6] You J, Chen W, Chen J, et al. The oncogenic role of ARG1 in progression and metastasis of hepatocellular carcinoma. Bio Med Res Int, 2018, 2018(1): 2109865. [7] 陶璇,王斌,陈虹,等. 肝细胞癌中精氨酸酶1和诱导型一氧化氮合成酶表达的临床意义及其相关性研究. 中华肝脏病杂志,2020,28(11):924-929. [8] Reynoso-Villalpando G L, Sevillano-Collantes C, Valle Y, et al. ApoB/ApoA1 ratio and non-HDL-cholesterol/HDL-cholesterol ratio are associated to metabolic syndrome in patients with type 2 diabetes mellitus subjects and to ischemic cardiomyopathy in diabetic women. Endocrinol Diab Nutr, 2019, 66(8): 502-511. [9] Walldius G, de Faire U, Alfredsson L, et al. Long-term risk of a major cardiovascular event by apoB, apoA-1, and the apoB/apoA-1 ratio—Experience from the Swedish AMORIS cohort: A cohort study. PLOS med, 2021, 18(12): e1003853. [10] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018年更新版). 实用肝脏病杂志,2018,21(2):177-186. [11] Cai X, Peng S, Xiao X, et al. Serum ApoB/ApoA1 ratio in patients with CHB and the occurrence of HBV related cirrhosis and HBV related hepatocellular carcinoma. Sci Rep UK, 2024, 14(1): 10996. [12] Riazi K, Azhari H, Charette J H, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol, 2022, 7(9): 851-861. [13] Mahmoudi A, Jamialahmadi T, Johnston T P, et al. Impact of fenofibrate on NAFLD/NASH: A genetic perspective. DrugDiscov Today, 2022, 27(8): 2363-2372. [14] Vitulo M, Gnodi E, Rosini G, et al. Current therapeutical approaches targeting lipid metabolism in NAFLD. Int J Mol Sci, 2023, 24(16): 12748. [15] Powell E E, Wong V W S, Rinella M. Non-alcoholic fatty liver disease. Lancet, 2021, 397(10290): 2212-2224. [16] Pierantonelli I, Svegliati-Baroni G. Nonalcoholic fatty liver disease: basic pathogenetic mechanisms in the progression from NAFLD to NASH. Transplantation, 2019, 103(1): e1-e13. [17] Sakurai Y, Kubota N, Yamauchi T, et al. Role of insulin resistance in MAFLD. Int J Mol Sci, 2021, 22(8): 4156. [18] Akhtar D H, Iqbal U, Vazquez-Montesino L M, et al. Pathogenesis of insulin resistance and atherogenic dyslipidemia in nonalcoholic fatty liver disease. J Clin Translat Hepatol, 2019, 7(4): 362. [19] Zhang M, Wu Z, Salas S S, et al. Arginase 1 expression is increased during hepatic stellate cell activation and facilitates collagen synthesis. J Cell Biochem, 2023, 124(6): 808-817. [20] Behbodikhah J, Ahmed S, Elyasi A, et al. Apolipoprotein B and cardiovascular disease: biomarker and potential therapeutic target. Metabolites, 2021, 11(10): 690. [21] Andraski A B, Sacks F M, Aikawa M, et al. Understanding HDL metabolism and biology through in vivo tracer kinetics. Arterioscler Thromb Vasc Biol, 2024, 44(1): 76-88. |